📊 YBGJ Key Takeaways
Is Yubo International Biotech Ltd (YBGJ) a Good Investment?
Yubo International faces imminent financial distress with negative stockholders' equity of $2.0M, severe liquidity constraints (0.24x current ratio), and only $8.1K cash against $843K annual operating burn. The company generated $12.4K in revenue against $1.2M operating losses, demonstrating a non-functional business model with insufficient runway and no viable path to profitability without significant capital infusion or restructuring.
Why Buy Yubo International Biotech Ltd Stock? YBGJ Key Strengths
- Gross margin of 66.1% indicates reasonable product-level economics if business scales
- Revenue growth of 256% YoY shows early market traction from minimal base
- Asset-light operations with minimal capital expenditure needs
YBGJ Stock Risks: Yubo International Biotech Ltd Investment Risks
- Balance sheet insolvency with negative stockholders' equity of $2.0M
- Critical liquidity crisis: current ratio of 0.24x with only $8.1K cash and $2.8M liabilities
- Unsustainable burn: $1.2M operating loss on $12.4K revenue with $843K annual cash burn
- Estimated 3-4 months of cash runway at current burn rate without financing
- Zero insider buying in 90 days suggests lack of management confidence
- High risk of bankruptcy or forced restructuring absent emergency capital raise
Key Metrics to Watch
- Quarterly cash position and burn rate trajectory
- Revenue growth sustainability and path to meaningful scale ($1M+ annually)
- Operating expense containment and break-even timeline
- Success of any emergency financing or capital raise activity
- Strategic alternatives including merger, acquisition, or dissolution
Yubo International Biotech Ltd (YBGJ) Financial Metrics & Key Ratios
💡 AI Analyst Insight
The current ratio below 1.0x warrants monitoring of short-term liquidity.
YBGJ Profit Margin, ROE & Profitability Analysis
YBGJ vs Healthcare Sector: How Yubo International Biotech Ltd Compares
How Yubo International Biotech Ltd compares to Healthcare sector averages
Sector benchmarks are approximate industry averages. Actual sector performance may vary.
Is Yubo International Biotech Ltd Stock Overvalued? YBGJ Valuation Analysis 2026
Based on fundamental analysis, Yubo International Biotech Ltd has mixed fundamental signals relative to the Healthcare sector in 2026.
Note: This is a fundamental analysis based on SEC filings. For P/E ratio, price targets, and market-based valuation, consult financial data providers. This is not investment advice.
Yubo International Biotech Ltd Balance Sheet: YBGJ Debt, Cash & Liquidity
YBGJ Revenue & Earnings Growth: 5-Year Financial Trend
5-Year Trend Summary: Yubo International Biotech Ltd's revenue has remained relatively flat over the 5-year period, with a 0% decline. The most recent EPS of $-0.02 indicates the company is currently unprofitable.
YBGJ Revenue Growth, EPS Growth & YoY Performance
YBGJ Quarterly Earnings & Performance
| Quarter | Revenue | Net Income | EPS |
|---|---|---|---|
| Q3 2025 | N/A | -$310.2K | $0.00 |
| Q2 2025 | N/A | -$230.3K | $0.00 |
| Q1 2025 | N/A | -$377.3K | $0.00 |
| Q3 2024 | N/A | $6.3K | $0.00 |
| Q2 2024 | N/A | -$316.7K | N/A |
| Q1 2024 | $3.5K | -$316.7K | N/A |
| Q3 2023 | $14.6K | $6.3K | N/A |
| Q2 2023 | $1.4K | -$316.7K | N/A |
Data sourced from SEC EDGAR 10-Q quarterly filings. Figures may represent quarterly or cumulative values.
Yubo International Biotech Ltd Dividends, Buybacks & Capital Allocation
YBGJ SEC Filings: Latest 10-K & 10-Q Analysis
Access official SEC EDGAR filings for Yubo International Biotech Ltd (CIK: 0000895464)
📋 Recent SEC Filings
❓ Frequently Asked Questions about YBGJ
What is the AI rating for YBGJ?
Yubo International Biotech Ltd (YBGJ) has an AI rating of STRONG SELL with 95% confidence, based on fundamental analysis of SEC EDGAR filings.
What are YBGJ's key strengths?
Claude: Gross margin of 66.1% indicates reasonable product-level economics if business scales. Revenue growth of 256% YoY shows early market traction from minimal base.
What are the risks of investing in YBGJ?
Claude: Balance sheet insolvency with negative stockholders' equity of $2.0M. Critical liquidity crisis: current ratio of 0.24x with only $8.1K cash and $2.8M liabilities.
What is YBGJ's revenue and growth?
Yubo International Biotech Ltd reported revenue of $12.4K.
Does YBGJ pay dividends?
Yubo International Biotech Ltd does not currently pay dividends.
Where can I find YBGJ SEC filings?
Official SEC filings for Yubo International Biotech Ltd (CIK: 0000895464) including 10-K, 10-Q, and 8-K reports are available on SEC EDGAR.
What is YBGJ's EPS?
Yubo International Biotech Ltd has a diluted EPS of $-0.01.
How is the AI analysis conducted?
Two independent AI systems — Claude (Anthropic) and ChatGPT (OpenAI) — analyze SEC EDGAR filings including 10-K annual reports and 10-Q quarterly reports. Each AI evaluates financial health, profitability ratios, balance sheet strength, and growth metrics. The combined rating reflects both perspectives for balanced insights.
Is YBGJ a good stock to buy right now?
Based on our AI fundamental analysis in April 2026, Yubo International Biotech Ltd has a STRONG SELL rating with 95% confidence. Review the strengths and risks sections above before making a decision. This is not investment advice.
Is YBGJ stock overvalued or undervalued?
Valuation metrics for YBGJ: ROE of N/A (sector avg: 15%), net margin of -8,736.7% (sector avg: 12%). Compare these metrics with sector averages to assess valuation.
Should I buy YBGJ stock in 2026?
Our dual AI analysis gives Yubo International Biotech Ltd a combined STRONG SELL rating for 2026. Revenue is data pending, with profitability at or below sector average. Always conduct your own research.
What is YBGJ's free cash flow?
Yubo International Biotech Ltd's operating cash flow is $-842.8K, with capital expenditures of $6.2K. FCF margin is -6,872.7%.
How does YBGJ compare to other Healthcare stocks?
Vs Healthcare sector averages: Net margin -8,736.7% (avg: 12%), ROE N/A (avg: 15%), current ratio 0.24 (avg: 2).